BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock Has Consensus Target Price of $88.60 According to Brokerages

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) have earned an average rating of “Moderate Buy” from the twenty-five research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, fifteen have assigned a buy rating and three have assigned a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $88.38.

Several research firms have recently issued reports on BMRN. HC Wainwright reaffirmed a “neutral” rating and issued a $60.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, September 10th. Barclays lifted their target price on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. Royal Bank Of Canada reduced their target price on shares of BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. Weiss Ratings cut shares of BioMarin Pharmaceutical from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, September 18th. Finally, Piper Sandler upped their price target on shares of BioMarin Pharmaceutical from $88.00 to $90.00 and gave the company an “overweight” rating in a research report on Tuesday, September 1st.

Institutional Trading of BioMarin Pharmaceutical

Institutional investors have recently modified their holdings of the business. Parkside Financial Bank & Trust increased its position in BioMarin Pharmaceutical by 70.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 187 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of BioMarin Pharmaceutical in the 2nd quarter worth approximately $39,000. Keating Financial Advisory Services Inc. acquired a new position in shares of BioMarin Pharmaceutical in the 2nd quarter worth approximately $56,000. Root Financial Partners LLC bought a new stake in shares of BioMarin Pharmaceutical in the 3rd quarter valued at $88,000. Finally, Parallel Advisors LLC boosted its stake in shares of BioMarin Pharmaceutical by 33.9% in the 1st quarter. Parallel Advisors LLC now owns 1,768 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 448 shares during the last quarter. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Trading Up 1.2%

Shares of BMRN stock opened at $56.00 on Monday. BioMarin Pharmaceutical has a twelve month low of $49.26 and a twelve month high of $70.98. The stock’s fifty day simple moving average is $61.04 and its 200 day simple moving average is $58.45. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $10.84 billion, a P/E ratio of 151.35, a P/E/G ratio of 0.61 and a beta of 0.22.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $0.95 by $0.25. The firm had revenue of $989.71 million during the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The business’s quarterly revenue was up 20.0% on a year-over-year basis. During the same period last year, the company earned $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, sell-side analysts predict that BioMarin Pharmaceutical will post 2.59 EPS for the current fiscal year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.